Sean T. O'Leary, MD, MPH, outlines 2026-2027 AAP influenza, COVID-19, and RSV guidance.
News|Articles|September 11, 2026
FAQ: What's new in COVID-19, RSV, and flu guidance?
Author(s)Contemporary Pediatrics Staff
Fact checked by: Morgan Ebert, Executive Editor
This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
Advertisement
Advertisement
The American Academy of Pediatrics (AAP) Committee on Infectious Diseases has issued 3 new policy statements outlining vaccine and immunization guidance for the 2026-2027 respiratory virus season, covering COVID-19, respiratory syncytial virus (RSV), and influenza.1-3 Published in Pediatrics, the statements update prior recommendations based on an evidence-based review of disease epidemiology, morbidity, mortality, and immunization safety and effectiveness data, developed in collaboration with external experts, the Vaccine Integrity Project, and other professional societies. Each statement is accompanied by a separate technical report detailing the supporting evidence.1-3
Related to this article
XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.
Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.
An updated AAP policy statement renews the call to ban raw milk sales, citing pathogen risks to children and pregnant people and an emerging H5N1 concern.
A clinician-reported misinformation tracker at Children's Hospital of Philadelphia found vaccines accounted for 53.8% of 234 entries and informed education on 28 topics.
At AAP 2026, Rana Hamdy, MD, discussed when to test children for group A strep, antibiotic selection, and strategies to improve prescribing.
The latest IDSA histoplasmosis update adds a consensus statement on severe disease and outlines when children with pulmonary infection warrant itraconazole therapy.
Advertisement
Advertisement